Blueprint Medicines (BPMC) Misses Q2 EPS by 14c
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Join SI Premium – FREE
Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.28), $0.14 worse than the analyst estimate of ($2.14). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $6.94 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
- Ribbon Communications (RBBN) Misses Q1 EPS by 2c; offers guidance
- Watsco (WSO) Misses Q1 EPS by 13c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
